Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Regorafenib

FDA-approved product (tablet, oral), marketed as Regorafenib, Stivarga.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Regorafenib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Colorectal adenocarcinoma
  • Colorectal cancer
  • Colorectal carcinoma
  • Colorectal neoplasm
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli33.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Regorafenib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Regorafenib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer

    NCT05933980 · start 2023-12-19

    Registered record
    Registry ID
    NCT05933980
    Conditions
    Colorectal Cancer; Liver Metastases; MSS
    Interventions
    Rego+Tori+Cele
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-12-19
    Completion
    2025-12-20
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Liver Metastases; MSS
    InterventionRego+Tori+Cele
    PhasePhase 2
    Registry statusUnknown

  • A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC

    NCT05773105 · start 2023-09-19

    Registered record
    Registry ID
    NCT05773105
    Conditions
    Advanced Hepatocellular Carcinoma
    Interventions
    Cadonilimab+regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2023-09-19
    Completion
    2026-03-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Hepatocellular Carcinoma
    InterventionCadonilimab+regorafenib
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

    NCT05194293 · start 2023-07-01

    Registered record
    Registry ID
    NCT05194293
    Conditions
    Stage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8
    Interventions
    Durvalumab; Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-07-01
    Completion
    2028-12-05
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IB Hepatocellular Carcinoma AJCC v8; Stage II Hepatocellular Carcinoma AJCC v8; Stage III Hepatocellular Carcinoma AJCC v8; Stage IIIA Hepatocellular Carcinoma AJCC v8
    InterventionDurvalumab; Regorafenib
    PhasePhase 2
    Registry statusActive not recruiting

  • Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

    NCT05731947 · start 2023-04-04

    Registered record
    Registry ID
    NCT05731947
    Conditions
    Colorectal Cancer; Solid Tumors
    Interventions
    Revumenib; Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2023-04-04
    Completion
    2025-06-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer; Solid Tumors
    InterventionRevumenib; Chemotherapy
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.

    NCT05673824 · start 2023-01-03

    Registered record
    Registry ID
    NCT05673824
    Conditions
    Nephrotoxicity
    Interventions
    Huaier Granule; VEGFR-TKIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-01-03
    Completion
    2025-12-01
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNephrotoxicity
    InterventionHuaier Granule; VEGFR-TKIs
    PhasePhase 2
    Registry statusCompleted

  • A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

    NCT05644392 · start 2022-11-25

    Registered record
    Registry ID
    NCT05644392
    Conditions
    Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
    Interventions
    Cadonilimab Injection; Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2022-11-25
    Completion
    2025-11-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
    InterventionCadonilimab Injection; Regorafenib
    PhasePhase 1
    Registry statusUnknown

  • Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma

    NCT05573282 · start 2022-10-16

    Registered record
    Registry ID
    NCT05573282
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Regorafenib combine with ICIs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-10-16
    Completion
    2026-01-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionRegorafenib combine with ICIs
    PhaseNot recorded
    Registry statusUnknown

  • TARGETed Therapy Drug MONITOring in DIGestive Oncology

    NCT05443087 · start 2022-08-29

    Registered record
    Registry ID
    NCT05443087
    Conditions
    Digestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST; Neuroendocrine Tumors
    Interventions
    Blood sampling to build population pharmacokinetics model
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2022-08-29
    Completion
    2027-06
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDigestive Cancer; Metastatic Colorectal Cancer; Hepatocellular Carcinoma; GIST +1 more
    InterventionBlood sampling to build population pharmacokinetics model
    PhaseNot applicable
    Registry statusRecruiting

  • Phase II Study of Regorafenib and Toripalimab Combined With RFA in Patients With CRCLM

    NCT05485909 · start 2022-07-25

    Registered record
    Registry ID
    NCT05485909
    Conditions
    Colorectal Cancer Liver Metastases
    Interventions
    Radiofrequency ablation; Regorafenib and Toripalimab Combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2022-07-25
    Completion
    2024-06-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Liver Metastases
    InterventionRadiofrequency ablation; Regorafenib and Toripalimab Combination
    PhasePhase 2
    Registry statusUnknown

  • Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy

    NCT05394740 · start 2022-06-06

    Registered record
    Registry ID
    NCT05394740
    Conditions
    Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma
    Interventions
    Regorafenib; Nivolumab; CapeOX; FOLFOX regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2022-06-06
    Completion
    2025-08-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Adenocarcinoma
    InterventionRegorafenib; Nivolumab; CapeOX; FOLFOX regimen
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib

    NCT04874207 · start 2021-10-22

    Registered record
    Registry ID
    NCT04874207
    Conditions
    Colorectal Cancer Metastatic
    Interventions
    Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-10-22
    Completion
    2025-04-11
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer Metastatic
    InterventionRegorafenib
    PhasePhase 4
    Registry statusCompleted

  • Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs

    NCT04996355 · start 2021-05-31

    Registered record
    Registry ID
    NCT04996355
    Conditions
    Colorectal Neoplasms; Organoids
    Interventions
    comprehensive treatment after MDT discussion
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2021-05-31
    Completion
    2024-05-30
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms; Organoids
    Interventioncomprehensive treatment after MDT discussion
    PhaseNot recorded
    Registry statusUnknown

  • A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.

    NCT04775862 · start 2021-02-21

    Registered record
    Registry ID
    NCT04775862
    Conditions
    Colon Cancer
    Interventions
    investigator choice re-challenge with anti EGFR Rx
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2021-02-21
    Completion
    2024-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer
    Interventioninvestigator choice re-challenge with anti EGFR Rx
    PhasePhase 2
    Registry statusUnknown

  • PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence

    NCT04787341 · start 2020-12-15

    Registered record
    Registry ID
    NCT04787341
    Conditions
    Colorectal Cancer
    Interventions
    Regorafenib; Panitumumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-12-15
    Completion
    2026-05-28
    Enrolment
    213

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionRegorafenib; Panitumumab
    PhasePhase 2
    Registry statusCompleted

  • Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

    NCT04450836 · start 2020-11-23

    Registered record
    Registry ID
    NCT04450836
    Conditions
    Metastatic Colorectal Cancer
    Interventions
    Regorafenib then Trifluridine/Tipiracil; Trifluridine/Tipiracil then Regorafenib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2020-11-23
    Completion
    2024-12-31
    Enrolment
    234

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer
    InterventionRegorafenib then Trifluridine/Tipiracil; Trifluridine/Tipiracil then Regorafenib
    PhasePhase 2
    Registry statusTerminated